{
  "fields": [{"id":"_id","type":"int"},{"id":"Chemical","type":"text"},{"id":"PMID","type":"numeric"},{"id":"Author,  year","type":"text"},{"id":"Study type","type":"text"},{"id":"Species/cell type","type":"text"},{"id":"Measurement","type":"text"},{"id":"Timepoint","type":"text"},{"id":"Effect measure","type":"text"},{"id":"Outcome","type":"text"},{"id":"Lower","type":"text"},{"id":"Upper","type":"numeric"},{"id":"Unit","type":"text"},{"id":"Remarks","type":"text"}],
  "records": [
    [17,"3,3',5,5'-tetrabromobisphenol A",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.31","1.62",4.69,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [22,"5-Fluorouracil",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.94","1.21",52.7,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [23,"5-Fluorouracil",21328588,"Mandenius, 2011","in vitro","HL-1","Respiration","","EC50","0.36","0.25",0.5,"µM",""],
    [29,"Aconitine",31975431,"Li, 2020","in vivo","Zebrafish","Mortality","48h","LD50","7.92","6.49",9.83,"µM",""],
    [30,"Aconitine",31975431,"Li, 2020","in vitro","H9c2","Cell viability","30m","IC50","4.411","3.68",5.59,"mM",""],
    [36,"Amitriptyline",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ peak count","","IC50","0.488109566666667","0.22",0.7,"µM","Peak count: number of contractions over a period of time."],
    [37,"Amitriptyline",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient width","","IC50","0.630555512192637","0.26",0.99,"µM","Width of the calcium transient"],
    [38,"Amitriptyline",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient amplitude","","IC50","0.489935966666667","0.24",0.68,"µM","Peak amplitude of the calcium peak as measurement for contractility"],
    [39,"Amitriptyline",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient rise time","","IC50","0.7650458001160785","0.45",0.95,"µM",""],
    [40,"Amitriptyline",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient decay time","","IC50","0.5265346341388603","0.31",0.75,"µM",""],
    [41,"Amitriptyline",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient spacing","","IC50","0.36593444453326907","0.16",0.56,"µM",""],
    [43,"Amitriptyline",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.9","2.14",3.97,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [44,"Amitriptyline",27130441,"Stoetzer, 2016","in vitro","NRVMs","Nav1.5","","IC50","13.0","12.0",14,"µM",""],
    [53,"Anthracene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.31","1.16",12.3,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [60,"Benz(a)anthracene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.57","1.2",13.2,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [69,"Benzo(e)pyrene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.44","1.18",11.8,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [70,"Benzo(e)pyrene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.77","1.2",18,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [81,"Bisphenol A",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","13.7","5.28",51.2,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [82,"Bisphenol A",34419494,"Hyun, 2021","in vitro","hiPSC-CMs","Ca2+ current","","IC50","6.9","5.800000000000001",8,"µM",""],
    [83,"Bisphenol A",34419494,"Hyun, 2021","in vitro","hiPSC-CMs","Na+ current","","IC50","56.5","38.6",74.4,"µM",""],
    [84,"Bortezomib",23315586,"Pointon, 2013","in vitro","hESC-CMs","ATP","","IC50","0.005","0.004",0.005,"µM","ATP as measurement for mitochondrial dysfunction"],
    [85,"Bortezomib",23315586,"Pointon, 2013","in vitro","hESC-CMs","ΔΨm","","IC50","0.006","0.005",0.006,"µM","ΔΨm: mitochondrial membrane potential"],
    [86,"Bortezomib",23315586,"Pointon, 2013","in vitro","hESC-CMs","Ca2+ mobilization","","IC50","0.06","0.059",0.06,"µM","Inhibition of Ca2+ mobilization compared to control"],
    [87,"Bortezomib",23315586,"Pointon, 2013","in vitro","hESC-CMs","ER integrity","","IC50","86.9","86.32",87.47,"µM","Measured with ER Tracker (imaging)"],
    [91,"Cadmium (Cd2+)",34255886,"Haverinen, 2021","in vitro","Rainbow trout CMs","Na+ current","","IC50","261.3","188.10000000000002",334.5,"µM",""],
    [92,"Carbachol",11750078,"Howard, 2002","in vitro","Rat cardiac membrane","Muscarinic receptor binding","","IC50","7.0","4.0",12,"nM","Adult rat cardiac membrane"],
    [93,"Carbachol",11750078,"Howard, 2002","in vitro","Rat cardiac membrane","Muscarinic receptor binding","","IC50","20.0","9.0",44,"nM","Neonatal rat cardiac membrane"],
    [98,"Chlorpyrifos",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","7.04","3.37",23.7,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [101,"Chlorpyrifos-methyl",19674799,"Tryfonos, 2009","in vitro","Sparus aurata","Contractility","30m","IC50","93.7","89.7",97.9,"µM",""],
    [105,"Daunorubicin",21328588,"Mandenius, 2011","in vitro","HL-1","Respiration","","EC50","0.12","0.12",0.14,"µM","Oxygen uptake rates, or respiration, provide direct information on the metabolic activity in cells and therefore on cellular homeostasis."],
    [114,"Di(2-ethylhexyl)phthalate ",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","1000.0","1.53",457000,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [115,"Diazinon",19674799,"Tryfonos, 2009","in vivo","Sparus aurata","Contractility","30m","IC50","164.0","458.0",170,"µM",""],
    [120,"Dibenz(a,c)anthracene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","8.56","2.72",47.6,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [125,"Dieldrin",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.38","1.17",12.7,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [126,"Doxorubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","ATP","","IC50","0.003","0.002",0.003,"µM","ATP as measurement for mitochondrial dysfunction"],
    [127,"Doxorubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","ΔΨm","","IC50","10.6","10.52",10.67,"µM","ΔΨm: mitochondrial membrane potential"],
    [128,"Doxorubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","Ca2+ mobilization","","IC50","40.78","40.5",41.05,"µM","Inhibition of Ca2+ mobilization compared to control"],
    [133,"Doxorubicin",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient width","","IC50","40.76670598599155","38.06",42.07,"µM","Width of the calcium transient"],
    [135,"Doxorubicin",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient rise time","","IC50","3.6320612638864014","2.14",5.12,"µM",""],
    [136,"Doxorubicin",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient decay time","","IC50","13.885542841387224","3.38",23.45,"µM",""],
    [143,"Doxorubicin",21328588,"Mandenius, 2011","in vitro","HL-1","Respiration","","EC50","0.43","0.38",0.5,"µM",""],
    [155,"Doxorubicin",15273722,"Kluza, 2004","in vitro","H9c2","Cell viability","24h","IC50","0.9","0.89",0.91,"µM",""],
    [158,"Endosulfan",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","3.81","2.3",7.22,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [159,"5-Fluorouracil",23315586,"Pointon, 2013","in vitro","hESC-CMs","ATP","","IC50","93.0","92.38",93.61,"µM","ATP as measurement for mitochondrial dysfunction"],
    [160,"5-Fluorouracil",23315586,"Pointon, 2013","in vitro","hESC-CMs","ΔΨm","","IC50","0.09","0.089",0.09,"µM","ΔΨm: mitochondrial membrane potential"],
    [161,"5-Fluorouracil",23315586,"Pointon, 2013","in vitro","hESC-CMs","Ca2+ mobilization","","IC50","0.03","0.037",0.038,"µM","Inhibition of Ca2+ mobilization compared to control"],
    [162,"5-Fluorouracil",23315586,"Pointon, 2013","in vitro","hESC-CMs","ER integrity","","IC50","0.06","0.05",0.06,"µM","Measured with ER Tracker (imaging)"],
    [165,"Idarubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","ATP","","IC50","0.13","0.12",0.13,"µM","ATP as measurement for mitochondrial dysfunction"],
    [166,"Idarubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","ΔΨm","","IC50","0.013","0.012",0.013,"µM","ΔΨm: mitochondrial membrane potential"],
    [167,"Idarubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","Ca2+ mobilization","","IC50","0.0134","0.0133",0.0134,"µM","Inhibition of Ca2+ mobilization compared to control"],
    [168,"Idarubicin",23315586,"Pointon, 2013","in vitro","hESC-CMs","ER integrity","","IC50","0.002","0.001",0.002,"µM","Measured with ER Tracker (imaging)"],
    [174,"Imatinib",23315586,"Pointon, 2013","in vitro","hESC-CMs","ATP","","IC50","15.7","15.59",15.8,"µM","ATP as measurement for mitochondrial dysfunction"],
    [175,"Imatinib",23315586,"Pointon, 2013","in vitro","hESC-CMs","ΔΨm","","IC50","26.0","25.82",26.17,"µM","ΔΨm: mitochondrial membrane potential"],
    [176,"Imatinib",23315586,"Pointon, 2013","in vitro","hESC-CMs","Ca2+ mobilization","","IC50","20.4","20.26",20.53,"µM","Inhibition of Ca2+ mobilization compared to control"],
    [177,"Imatinib",23315586,"Pointon, 2013","in vitro","hESC-CMs","ER integrity","","IC50","52.0","51.65",52.34,"µM","Measured with ER Tracker (imaging)"],
    [179,"Imatinib",28315715,"Chambers, 2017","in vitro","H9c2","Cell viability","24h","IC50","26.2","19.1",33.3,"µM",""],
    [188,"Imatinib",18664550,"Will, 2008","in vitro","H9c2","ATP","24h","IC50","30.53","29.07",31.99,"µM","Glucose containing media"],
    [189,"Imatinib",18664550,"Will, 2008","in vitro","H9c2","ATP","24h","IC50","29.17","27.4",30.94,"µM","Galactose containing media"],
    [197,"Lead chloride",28836190,"Mattos, 2017","in vitro","Guinea pig CMs","Ca2+ current","","IC50","18.0","10.0",26,"µM","Cav1.2 channel (ICa)"],
    [202,"Lindane",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","5.72","1.89",4380,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [209,"Mitoxantrone",23315586,"Pointon, 2013","in vitro","hESC-CMs","ATP","","IC50","0.4","0.39",0.4,"µM","ATP as measurement for mitochondrial dysfunction"],
    [210,"Mitoxantrone",23315586,"Pointon, 2013","in vitro","hESC-CMs","ΔΨm","","IC50","3.2","3.17",3.22,"µM","ΔΨm: mitochondrial membrane potential"],
    [211,"Mitoxantrone",23315586,"Pointon, 2013","in vitro","hESC-CMs","Ca2+ mobilization","","IC50","3.3","3.27",3.32,"µM","Inhibition of Ca2+ mobilization compared to control"],
    [212,"Mitoxantrone",23315586,"Pointon, 2013","in vitro","hESC-CMs","ER integrity","","IC50","3.4","3.37",3.42,"µM","Measured with ER Tracker (imaging)"],
    [220,"Mitoxantrone",15273722,"Kluza, 2004","in vitro","H9c2","Cell viability","24h","IC50","1.6","1.3",1.9,"µM",""],
    [232,"Nifedipine",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ peak count","","IC50","0.933096566666667","0.38",1.72,"µM","Peak count: number of contractions over a period of time."],
    [233,"Nifedipine",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient width","","IC50","1.2886851277115852","0.86",1.7,"µM","Width of the calcium transient"],
    [234,"Nifedipine",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient amplitude","","IC50","0.361144833333333","0.24",0.46,"µM","Peak amplitude of the calcium peak as measurement for contractility"],
    [235,"Nifedipine",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient rise time","","IC50","0.6551296611460257","0.4",0.8,"µM",""],
    [236,"Nifedipine",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient decay time","","IC50","1.4163737617107073","0.11",6.14,"µM",""],
    [237,"Nifedipine",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient spacing","","IC50","0.2542488299647862","0.03",0.84,"µM",""],
    [240,"Nifedipine",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","20.8","8.7",67.4,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [245,"Paraoxon",19674799,"Tryfonos, 2009","in vivo","Sparus aurata","Contractility","30m","IC50","3.2","3.17",3.32,"µM",""],
    [250,"Parathion-methyl",19674799,"Tryfonos, 2009","in vivo","Sparus aurata","Contractility","30m","IC50","80.3","75.16",85.7,"µM",""],
    [255,"Permethrin",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.49","1.21",12.6,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [260,"Phenanthrene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","37.5","4.08",836,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [261,"Phenanthrene",33906022,"Abramochkin, 2021","in vitro","Navaga cod CMs","K+ current","","IC50","1.95","1.85",2.05,"µM","Atrial Ikr potassium current"],
    [262,"Phenanthrene",33906022,"Abramochkin, 2021","in vitro","Navaga cod CMs","K+ current","","IC50","2.2","1.9",2.5,"µM","Ventricular Ikr potassium current"],
    [267,"Pyrene",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","2.36","1.17",12.3,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [270,"Rosiglitazone",24249632,"Mishra, 2014","in vitro","H9c2","Cell viability","24h","IC50","55.0","50.0",60,"µM",""],
    [271,"Rosiglitazone",21774756,"Szebeni, 2011","in vitro","Canine VCMs","Ito","","IC50","25.2","22.5",27.9,"µM","Ito: Cardiac transient outward potassium current"],
    [272,"Rosiglitazone",21774756,"Szebeni, 2011","in vitro","Canine VCMs","Ikr","","IC50","72.3","63.0",81.6,"µM","Ikr: Rapid delayed rectifier potassium current"],
    [273,"Rosiglitazone",21774756,"Szebeni, 2011","in vitro","Canine VCMs","Ca2+ current","","IC50","82.5","73.1",91.9,"µM",""],
    [275,"Sibutramine",18829731,"Kim, 2008","in vitro","CHO cells","hERG","","IC50","2.41","1.9",2.9,"µg/mL",""],
    [276,"Sibutramine",18829731,"Kim, 2008","in vitro","ARVMs","Na+ current","","IC50","7.72","5.98",9.46,"µg/mL",""],
    [277,"Sibutramine",18829731,"Kim, 2008","in vitro","ARVMs","Ca2+ current","","IC50","2.79","2.32",3.26,"µg/mL",""],
    [283,"Tebuconazole",35202779,"Miranda, 2022","in vitro","Mouse VCMs","Ca2+ current","","IC50","33.2","25.800000000000004",40.6,"µM","L-type calcium channel inhibitor"],
    [284,"Tebuconazole",35202779,"Miranda, 2022","in vitro","Mouse VCMs","K+ current","","IC50","5.7","4.2",7.2,"µM","IK potassium current inhibition"],
    [286,"Telmisartan",18664324,"Tu, 2008","in vitro","Oocytes","hKv1.5","","IC50","2.25","1.28",3.22,"µM","Peak current"],
    [287,"Telmisartan",18664324,"Tu, 2008","in vitro","Oocytes","hERG","","IC50","24.35","19.29",29.41,"µM",""],
    [288,"Telmisartan",18664324,"Tu, 2008","in vitro","Oocytes","hKv1.5","","IC50","0.82","0.43",1.21,"µM","1.5 second end-pulse current"],
    [305,"Verapamil",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ peak count","","IC50","0.315762326666667","0.1",0.64,"µM","Peak count: number of contractions over a period of time."],
    [306,"Verapamil",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient width","","IC50","0.07754059017887538","0.01",0.13,"µM","Width of the calcium transient"],
    [307,"Verapamil",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient amplitude","","IC50","0.0212289733333333","0.01",0.03,"µM","Peak amplitude of the calcium peak as measurement for contractility"],
    [308,"Verapamil",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient rise time","","IC50","0.13900017643224588","0.01",0.2,"µM",""],
    [309,"Verapamil",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient decay time","","IC50","0.0349676443728653","0.02",0.04,"µM",""],
    [310,"Verapamil",25538221,"Pointon, 2015","in vitro","hiPSC-CMs","Ca2+ transient spacing","","IC50","0.019115175830544666","0.01",0.03,"µM",""],
    [312,"Verapamil",28069985,"Pointon, 2017","in vitro","3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)","Peak amplitude","","IC50","5.16","2.02",13.1,"µM","Peak amplitude of the contraction peak."],
    [313,"Verapamil",28069985,"Pointon, 2017","in vitro","3D cardiac microtissue (hiPSC-CMs, hCMECs, hCFs)","Peak count","","IC50","0.1690375987746757","0.15883350098270407",42,"µM","Peak count: number of contractions over a period of time."],
    [314,"Verapamil",33078833,"Blanchette, 2020","in vitro","hiPSC-CMs","Cell viability","90 min","TDVF05","5.87","2.19",26.6,"42","TDVF05: toxicodynamic variability factor. Ratio between the effective concentration (EC) for the median individual and that for a sensitive individual (5th percentile of the population), see ref. No EC values were reported."],
    [315,"Verapamil",21328588,"Mandenius, 2011","in vitro","HL-1","Respiration","","EC50","32.0","31.0",36,"µM",""]
]}